| For: | Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World J Diabetes 2022; 13(12): 1168-1183 [PMID: 36578872 DOI: 10.4239/wjd.v13.i12.1168] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v13/i12/1168.htm |
| Number | Citing Articles |
| 1 |
Rifika Bansal, Ravi Kant, Yogesh Bahurupi, Ashwarya Gupta. Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review. Indian Journal of Endocrinology and Metabolism 2025; 29(3): 260 doi: 10.4103/ijem.ijem_372_24
|
| 2 |
Jun‐Ichirou Mori, Koh Yamashita, Toru Aizawa. Characterization of Patients With Type 2 Diabetes Experiencing Severe Hypoglycemia Exclusively due to Dipeptidyl Peptidase‐4 Inhibitor Monotherapy. Geriatrics & Gerontology International 2025; doi: 10.1111/ggi.70240
|
| 3 |
Alka Bishnoi, Amitabh Sur, Bensley Gonsalves, Bhawna Atri, Soumik Goswami, Venkatesan Ravindranath, Vivek Patel, Hiren Prajapati, Disha Shah. Taking a Closer Look at Gliclazide – Benefits Beyond Glycemic Control. International Journal of Diabetes and Technology 2025; 4(3): 49 doi: 10.4103/ijdt.ijdt_10_25
|
